8-K
EXOZYMES INC. (EXOZ)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
December11, 2025
EXOZYMES
INC.
(Exact name of registrant as specified in its charter)
| Nevada | 001-42204 | 83-4550057 |
|---|---|---|
| (State<br> or other jurisdiction<br><br> <br>of<br> incorporation) | (Commission<br><br> <br>File<br> Number) | (I.R.S.<br> Employer<br><br> <br>Identification<br> No.) |
750Royal Oaks Drive, Suite 106
Monrovia,CA 91016
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (626) 415-1488
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common<br> Stock | EXOZ | Nasdaq<br> Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item8.01 — Other Events.
Attached is a press release eXoZymes Inc. dated December 11, 2025, related to the scale up of NCT production using exozymes.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
|---|---|
| Exhibits | Description<br> of Exhibit |
| --- | --- |
| 99.1 | Press<br> Release dated December 11, 2025, related to NCT production. |
| 104 | Cover<br> Page Interactive Data File (embedded within the Inline XBRL Document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date:<br>December 12, 2025 | EXOZYMES<br> INC. | |
|---|---|---|
| By | /s/ Fouad Nawaz | |
| Fouad<br> Nawaz, | ||
| Vice<br> President, Finance |
Exhibit 99.1
eXoZymes achieves 100× scale-up of NCT productionusing exozymes, demonstrating near-perfect feedstock conversion.
Los Angeles, CA — December 11, 2025 — Today, eXoZymes Inc.(NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticalsand new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production processusing its proprietary exozyme-based, cell-free biomanufacturing platform. This effort, with a conversion level of over 99% from feedstockto product, marks a major milestone in the scalability of the exozymes platform.
“Scaling a complex biocatalytic reaction by 100× while sustaininghigh feedstock conversion strengthens our belief that exozymes will form the foundation of the next generation of biomanufacturing,” said Michael Heltzen, CEO of eXoZymes. “We’re very enthusiastic about this progress and see it as an important inflectionpoint in demonstrating that cell-free, enzyme-driven systems can be engineered to operate reliably at scale. This truly opens the doorto producing molecules that have historically been constrained by traditional manufacturing approaches.”
The scaled reaction maintained exceptionally high conversion efficiency, demonstrating near-complete transformation of input feedstock into target product under large-volume operating conditions. This performance confirms that the exozyme-driven process not only scales linearly but can match - or exceed - conversion levels observed at smaller scales. The batch production was executed using standardized protocols under partner-operated conditions by Cayman Chemical, underscoring the robustness, transferability, and scalability of the process and technology.
Dr. Tyler Korman, CSO of eXoZymes, adds, “Scaling while preservingreaction performance has historically been challenging, and this outcome supports the growing body of evidence that cell-free enzyme productionpathways - aka exozymes systems - can overcome fundamental limitations associated with traditional biomanufacturing approaches. Achievingover 99% conversion at scale is a significant validation of our exozyme biosolution - both from a scientific as well as a commercial pointof view.”
Cayman Chemical and eXoZymes are working on the isolation process for NCT as well as still analyzing the data from the experiment. Additional technical details are expected to be published in a subsequent press release following completion of downstream analysis and NCT extraction. Due to the magnitude of the work and the upcoming holidays, this additional information should not be expected until early 2026.
About Cayman
Cayman Chemical helps make research possible by providing products and services to scientists worldwide. Cayman’s collection includes high-quality biochemicals, assay kits, antibodies, and proteins, empowering researchers to understand the biological mechanisms of health and disease and develop new therapies. Cayman’s scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, and fatty acids, and are highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, Cayman offers a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.
Learn more at www.caymanchem.com
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature’s own natural processes to produce very valuable natural products, via a commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, nutraceuticals and medicines.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced “exozymes” as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more at exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “potential,” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes